This systematic review evaluated tirzepatide as adjunctive therapy to insulin in adults with T1D and overweight or obesity.<h4>Methods</h4>This review followed PRISMA 2020 and was registered in PROSPERO (CRD420261335230). Here, INS is linked to Obesity.